Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
Johnson & Johnson Enterprise Innovation Inc.
NRG Oncology
Eastern Cooperative Oncology Group
R-Pharm
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Radiation Therapy Oncology Group
Brown University
Incyte Corporation
Groupe Oncologie Radiotherapie Tete et Cou
Groupe Oncologie Radiotherapie Tete et Cou
AVEO Pharmaceuticals, Inc.
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Shanghai Miracogen Inc.
Bristol-Myers Squibb
Radiation Therapy Oncology Group
Bristol-Myers Squibb
Groupe Oncologie Radiotherapie Tete et Cou
Incyte Corporation
Gruppo Oncologico del Nord-Ovest
Merck KGaA, Darmstadt, Germany
Associazione Volontari Pazienti Oncologici
Merck KGaA, Darmstadt, Germany
University of Alabama at Birmingham